Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Repare Therapeutics Inc stock PB Ratio (=0.99) is close to 2-year high of 0.99.
The historical rank and industry rank for Repare Therapeutics's PB Ratio or its related term are showing as below:
RPTX'
s PB Ratio Range Over the Past 10 Years
Min: 0.3 Med: 1.57 Max: 5.48
Current: 0.99
During the past 8 years, Repare Therapeutics's highest PB Ratio was 5.48. The lowest was 0.30. And the median was 1.57.
RPTX's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.82
vs RPTX: 0.99
During the past 12 months, Repare Therapeutics's average Book Value Per Share Growth Rate was -34.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -19.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Repare Therapeutics was -13.50% per year. The lowest was -19.80% per year. And the median was -16.65% per year.
Back to Basics: PB Ratio
Repare Therapeutics (NAS:RPTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Repare Therapeutics PB Ratio Related Terms
Repare Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Repare Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Repare Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Repare Therapeutics (RPTX) has a PB Ratio of 0.99 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Repare Therapeutics and its competitors. This is 37% below median its historical median of 1.57. Over the past decade, Repare Therapeutics' PB Ratio has ranged from 0.30 to 5.48.
Is Repare Therapeutics' PB Ratio too high?
Repare Therapeutics' current PB Ratio of 0.99 is 37% below median its 10-year median of 1.57. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 5.48. The Biotechnology industry median PB Ratio is 2.82. Repare Therapeutics' value of 0.99 is 64.9% below this industry median. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' PB Ratio compare to MGNX and THAR?
Repare Therapeutics' PB Ratio of 0.99 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.82. Repare Therapeutics' value of 0.99 is 64.9% below this benchmark. Historically, Repare Therapeutics' own PB Ratio has ranged from 0.30 to 5.48 over the past decade. While the company's 10-year median is 1.57 vs. the industry median of 2.82, Repare Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repare Therapeutics's current PB Ratio of 0.99 is 64.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Repare Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repare Therapeutics's current PB Ratio is 0.99, which is 37% below median its own 10-year median of 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current PB Ratio of 0.99. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current PB Ratio is 0.99, which is 37% below median its 10-year median of 1.57 and 64.9% below the Biotechnology industry median of 2.82. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current PB Ratio is 0.99 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repare Therapeutics (RPTX) Overvalued in 2026?
Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued.
The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.
Key valuation signals for RPTX:
PB Ratio: 0.99 (37% below median its 10-year median of 1.57)
GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
Industry Position: 64.9% below the Biotechnology median
No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score
Get the complete analysis for RPTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPTX has been successfully added to your 
